The pharmaceutical industry has bounced back in 2024. After barely growing by 0.5% in 2023, the sector has made a solid recovery, with output expected to rise by 4.6% and sales by 5.1% this year. Dividend-paying pharma stocks have also gained a lot of attention as investors look for reliable income in an unpredictable market.
Bristol Myers Squibb (BMY) has recently stepped into the spotlight, especially with Jefferies upgrading its rating from "Hold" to "Buy." This is a big deal because analysts had been on the fence about the stock for quite some time.
